TX-TXONE-NETWORKS
31.1.2024 07:01:24 CET | Business Wire | Press release
TXOne Networks, a leader in Cyber-Physical Systems (CPS) security, published its 2023 annual report detailing a growing range of cybersecurity issues facing global industries. The Crisis of Convergence: OT/ICS Cybersecurity 2023, which is publicly available for free download, details diverse intensifying challenges, including growth in attacks via Ransomware-as-a-Service (RaaS) models, exploitation of supply-chain vulnerabilities and prevalence of state-sponsored hackers and other politically motivated actors in the wake of geopolitical issues.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130429836/en/
(Graphic: Business Wire)
TXOne Networks in September 2023 surveyed 405 key IT and OT security decision-makers from across multiple global markets and sectors including automotive, pharmaceuticals and biotechnology, chemical, general manufacturing, oil, and gas and transportation. The Crisis of Convergence: OT/ICS Cybersecurity 2023 distills the survey findings, alongside extensive TXOne Networks threat research from 545 cybersecurity incidents around the world in 2023.
“The threat landscape has intensified significantly in the industrial manufacturing and critical infrastructure sectors, leading to destructive events, economic losses, and potential risks to human safety...,” reads the TXOne Networks report, which was produced in collaboration with Frost & Sullivan. “Organizations emphasize the protection of critical OT (Operational Technology) assets as a top priority, with data security being a key investment area within their OT security budget allocations. ... Organizations are also seeking to invest in strengthening the resilience of their technological infrastructure and are turning to innovative approaches like Cyber-Physical Systems Detection and Response (CPSDR), which integrates OT expertise across various domains. This enhances OT security posture and resilience against evolving threats, enabling organizations to better protect their operations and ensure resilience in the face of a constantly changing threat environment.”
The Crisis of Convergence: OT/ICS Cybersecurity 2023 explores a range of topics relevant to contemporary OT/ICS cybersecurity:
- Ransomware threats
- OT system maintenance and Information Technology (IT) integration concerns
- Nation-state cyberattacks and implications
- Dedicated teams for OT and Industrial Control System (ICS) security management
- OT/ICS cybersecurity investment
- New regulations and standards propelling OT/ICS defense
- Supply-chain Integrity
“The Crisis of Convergence: OT/ICS Cybersecurity 2023 is the result of a thorough research and technical analysis that is aimed at delivering up-to-date insights into the global threat landscape and the tactics that malicious actors employ to launch attacks,” said Terence Liu, chief executive officer (CEO) of TXOne Networks. “The findings are clear. Organizations must move well beyond regulatory compliance in their OT/ICS cybersecurity strategies if they are to successfully adapt for the constantly evolving threat. Safeguarding the availability, reliability and security of revenue-generating operations will depend on new governance structures, enhanced team and technical capabilities, integration of advanced threat detection and response into cybersecurity frameworks and risk management across the supply chain.”
Download TXOne Networks’ The Crisis of Convergence: OT/ICS Cybersecurity 2023.
About TXOne Networks
TXOne Networks offers cybersecurity solutions that ensure the reliability and safety of industrial control systems and operational technology environments. TXOne Networks works together with both leading manufacturers and critical infrastructure operators to develop practical, operations-friendly approaches to cyber defense. TXOne Networks offers both network-based and endpoint-based products to secure the OT network and mission-critical devices using a real-time, defense-in-depth approach. www.txone.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130429836/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
